LafargeHolcim and Jalalabad Liver Trust Host Free Medical Camp

LafargeHolcim Bangladesh PLC will invest Tk 180 crore in a new industrial-use mill at its Surma plant in Sunamganj’s Chhatak to enhance energy efficiency and operational reliability. Despite a 14% year-on-year profit decline to Tk 139.1 crore in Q1 2025—driven by rising fuel costs and declining cement prices—the company’s revenue rose 3% to Tk 851.5 crore, reflecting stable market demand.

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

In Q3 of FY 2024–25, Crown Cement's profit surged 76% year-on-year to Tk 30.20 crore, driven by a 30% revenue growth to Tk 1,192.20 crore, attributed to a 30.14% increase in sales volume and a slight 0.46% price rise. Earnings per share rose to Tk 2.03 from Tk 1.15.

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.